First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors (NCT06554795)
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants With Advanced/Metastatic Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Who can join: Review the eligibility criteria below.
Location: Site USA12-0 — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- Site USA12-0 — Los Angeles, California
- Site USA08-0 — Newport Beach, California
- Site USA06-0 — Washington D.C., District of Columbia
- Site USA02-0 — Florida City, Florida
- Site USA11-0 — Chicago, Illinois
- Site USA03 — Huntersville, North Carolina
- Site USA05-0 — Philadelphia, Pennsylvania
- Site USA07-0 — Nashville, Tennessee
- Site USA09-0 — West Valley City, Utah
- AUS03-0 — North Ryde, New South Wales
- AUS01-0 — Randwick, New South Wales
- AUS02-0 — Nedlands, Washington
- Site CHN24-0 — Hefei, Anhui
- Site CHN39-0 — Hefei, Anhui
- Site CHN28-0 — Beijing, Beijing Municipality
- Site CHN13-0 — Jilin City, Changchun
- Site CHN16-0 — Chongqing, Chongqing Municipality
- Site CHN20-0 — Fuzhou, Fujian
- Site CHN32-0 — Nanning, Guangxi
- Site CHN08-0 — Harbin, Heilongjiang
- Site CHN23-0 — Harbin, Heilongjiang
- Site CHN03-0 — Luoyang, Henan
- Site CHN09-0 — Zhengzhou, Henan
- Site CHN25-0 — Zhengzhou, Henan
- Site CHN34-0 — Wuhan, Hubei
📞 Contact the Study Coordinator
Phone: (201) 503-5410
Email: milly.zang@dualitybiologics.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor, Adult
- A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody — Sarasota, Florida
- First-in-Human Study of ICT01 in Patients With Advanced Cancer — Gilbert, Arizona
- A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors — Los Angeles, California
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab — Los Angeles, California
- A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial — Scottsdale, Arizona
- A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression — Gilbert, Arizona
Explore by condition: All Solid Tumor, Adult clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.